###### Strengths and limitations of this study

This will be the first study to compare prognosis of the subgroups of chronic obstructive pulmonary disease and asthma with chronic airflow obstruction (CAO) divided by the CT scan findings of emphysema.The prognosis of asthma with CAO was evaluated in the period after inhaled corticosteroids had become first-line therapy for asthma.This is a large-scale cohort study, but the data are derived from a single centre and the study is retrospective.

Introduction {#s1}
============

Chronic obstructive pulmonary disease (COPD) is characterised by not fully reversible airflow obstruction in patients with risk factors (tobacco, occupation and air pollution).[@R1] It is also recognised that various respiratory diseases (RD) other than COPD such as asthma, bronchiectasis or old tuberculosis may have similar chronic airflow obstruction (CAO) as a postbronchodilator forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) persistently under 0.7.[@R2; @R3; @R4] Recently, it has been recognised that emphysematous change as assessed by high-resolution CT (HRCT) scan is a more important prognostic factor than FEV1 in patients with COPD.[@R5] However, the clinical significance of HRCT-diagnosed emphysema in the prognosis of other RD such as asthma with fixed airflow obstruction is not well known.

We hypothesised that HRCT-diagnosed emphysema is associated with the prognosis of the patients with CAO not limited to patients with COPD. We sought to compare the prognosis and prognostic factors of the phenotypes of COPD and asthma with CAO classified by the HRCT findings of emphysema. We also examined the prevalence of these phenotypes and other RD in consecutive patients with CAO to clarify the impact of differentiating these phenotypes.

Methods {#s2}
=======

Patients {#s2a}
--------

We reviewed 1960 consecutive patients older than 40 years of age with initial postbronchodilator FEV1/FVC\<0.7 who presented to the Saitama Cardiovascular and Respiratory Center (a tertiary referral centre with 155 beds for RD) in Saitama, Japan, from 2000 through 2011. CAO was defined to be an FEV1/FVC ratio of \<0.7 after bronchodilator use throughout the observation period. We excluded 326 (16.6%) patients who did not undergo an HRCT examination or who did not receive a complete diagnosis, 133 (6.8%) patients who had lung cancer at the entry examination, and 229 (11.7%) patients whose postbronchodilator FEV1/FVC recovered to \>0.7 during the observation period. Finally, we studied 1272 patients with CAO who underwent an HRCT examination.

Study design {#s2b}
------------

This was a retrospective cohort study in which clinical data were collected from medical records. Survival status was obtained from medical records and/or telephone interviews.

All deaths were classified into the following five groups: (1) primary RD, (2) lung cancer, (3) malignancy other than lung cancer, (4) respiratory infectious diseases and (5) other or unknown. The HRCT study was ordered by the chest physician in charge for a closer examination of symptoms or evaluation of the diseases. The algorithm used to classify CAO is shown in online supplementary [figure S1](#BMJOPEN2013003541F1){ref-type="fig"}. All tests involved in the study were taken in a stable phase, with no evidence of any exacerbations for at least 6 weeks. HRCT images obtained within 6 months of the initiation time were considered acceptable for the evaluation. Medications used from the start of the observation period were also recorded.

![Phenotypes of chronic airflow obstruction (CAO). CAO was defined as postbronchodilator FEV1/FVC\<0.7 throughout the observation period. Patients were classified by the high-resolution CT findings of emphysema and other clinical examinations. FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; RD, respiratory diseases.](bmjopen2013003541f01){#BMJOPEN2013003541F1}

The criteria used to classify patients with CAO included the following: (1) COPD with emphysema: presence of macroscopic emphysema on HRCT with a smoking history of at least 10 pack-years without other respiratory complications; (2) COPD without emphysema: no macroscopic emphysema on HRCT with a smoking history of at least 10 pack-years without other respiratory complications; (3) asthma with emphysema: presence of macroscopic emphysema on HRCT and fit the criteria for asthma[@R6]; asthma symptoms or history, a postbronchodilator increase in FEV1 of \>12% and 200 mL, evidence of at least one of the following, sputum eosinophilia (\>3%) or increased exhaled nitric oxide (\>30 ppb) or evidence of atopy; (4) asthma without emphysema: no macroscopic emphysema on HRCT and fit the above criteria for asthma; (5) other RD with emphysema: presence of macroscopic emphysema on HRCT and fulfil the criteria for other RD except asthma; and (6) other RD without emphysema: no macroscopic emphysema on HRCT and presence of other RD except asthma. Special care was taken to diagnose possible lung diseases by respiratory specialists and radiology specialists in our clinic for more than a decade, and all the necessary complementary tests were performed in this respect. Old pulmonary tuberculosis and pneumoconiosis were diagnosed by CT findings and history. Non-tuberculous mycobacterial lung diseases were diagnosed by the2007 American Thoracic Society (ATS)/Infectious Disease Society of America (IDSA) diagnostic criteria.[@R7] Chronic hypersensitivity pneumonitis,[@R8] diffuse panbronchiolitis,[@R9] pulmonary Langerhans cell histiocytosis,[@R10] sarcoidosis,[@R11] bronchial diseases due to rheumatoid arthritis,[@R12] bronchiolitis obliterans[@R13] and other miscellaneous diseases were diagnosed as previously described.

High-resolution CT {#s2c}
------------------

HRCT scans were performed in full inspiration with a HiSpeed Advantage CT scanner (GE Medical Systems, Milwaukee, Wisconsin, USA) with a slice thickness of 1 mm, scanning time of 1 s, voltage of 140 kV, tube current of 200 mA and field of view of 20 cm. The presence of emphysema was defined as well-demarcated areas of decreased attenuation in comparison with a contiguous normal lung and marginated by a very thin or no wall with upper zone predominance. The presence of emphysema and CT diagnosis were determined by two radiologists with extensive experience in the diagnosis of RD; all were blind to other researchers. The CT findings of usual interstitial pneumonia or other interstitial pneumonia were diagnosed based on the 2002 ATS/European Respiratory Society (ERS) classification.[@R14] The presence of bronchiectasis was based on criteria by Naidich *et al*[@R15] Mild dilation of the airways in COPD was not considered as bronchiectasis.

Pulmonary function tests {#s2d}
------------------------

Pulmonary function tests were performed with a CHESTAC-8800 spirometer (Chest MI Corp, Tokyo, Japan). Predicted values of spirometric measurements were derived from the guidelines for pulmonary function tests issued by the ATS.[@R16] Spirometry was performed before and 30 min after inhalation of 200 µg of salbutamol, and the data obtained after inhalation of salbutamol were used for evaluation.

Statistical analysis {#s2e}
--------------------

Categorical baseline characteristics are summarised by per cent, and continuous characteristics are reported as mean±SD. Comparisons between subgroups for descriptive summaries were performed by analysis of variance. We compared the baseline characteristics to investigate potential risk factors of mortality. We chose the variables for entry into univariate Cox regression analysis from the results that showed significant effectors with previously recognised clinical significance: clinical phenotype, sex, age, body mass index (BMI), smoking history (1 cigarette×year), current smoking, FVC, FEV1, FEV1/FVC, FEV1 reversibility to bronchodilators, annual change in FEV1 and medications used from the start of observation. We then performed multivariate Cox regression analysis with backward variable selection.

Survival in each patient subgroup was estimated by the Kaplan-Meier analysis. Mortality rates from any cause for two clinical phenotypes were compared with a log-rank test. Time was defined from initial examination until 1 March 2012 or until death or loss to follow-up before 1 March 2012.

Differences in causes of mortality were analysed by the Fisher-Freeman-Halton test, and risk for de novo lung cancer was analysed by multiple logistic regression analysis with Firth's bias reduction. A p value of \<0.05 was considered statistically significant. All data were analysed with SAS V.9.1.3 SP4 (SAS Institute Inc, Cary, North Carolina, USA).

Results {#s3}
=======

Prevalence of COPD, asthma and other RD in patients with CAO {#s3a}
------------------------------------------------------------

Of the 1272 patients with postbronchodilator FEV1/FVC\<0.7 throughout the observation period, 517 (40.6%) had COPD with emphysema, 104 (8.2%) had COPD without emphysema, 178 (14%) had asthma with emphysema, 169 (13.3%) had asthma without emphysema, 128 (10%) had other RD with emphysema and 176 (13.8%) had other RD without emphysema ([figure 1](#BMJOPEN2013003541F1){ref-type="fig"}). Other RD with or without emphysema are shown in online supplementary [table S1](#BMJOPEN2013003541TB1){ref-type="table"}.

###### 

Characteristics of the patients with chronic airflow obstruction

                                               COPD         Asthma       Other RD                                               
  -------------------------------------------- ------------ ------------ ------------- ------------- ------------ ------------- ---------
  Number                                       517, 40.6%   104, 8.2%    178, 13.9%    169, 13.3%    128, 10.1%   176, 13.8%    
  Age                                          69.1±8.3     70.4±7.2     67.6±7.9      64.5±9.5      70.6±7.9     65.0±11.8     \<0.001
  Female sex (n, %)                            20, 3.9      10, 9.6      21, 11.8      55, 32.7      4, 3.1       66, 37.5      \<0.001
  Body mass index                              21.2±3.6     23.2±2.6     21.9±3.3      23.0±3.2      22.2±3.6     22.3±3.3      \<0.001
  Never smoker (n, %)                          0            0            0             62, 36.9      0            79, 44.9      \<0.001
  Smoking index (pack-year)                    67.2±34.7    57.6±28.3    59.3±29.0     22.9±24.5     65.8±34.1    20.5±25.4     \<0.001
  %FVC                                         85.5±19.4    86.4±18.9    86.0±19.2     86.1±18.4     84.6±22.1    76.4±18.5     \<0.001
  %FEV1                                        59.6±24.4    71.2±21.9    56.0±21.8     66.5±22.1     70.6±28.5    65.7±21.3     \<0.001
  FEV1/FVC                                     44.7±12.7    53.3±9.9     44.4±11.9     52.7±11.1     53.2±12.8    56.0±11.8     \<0.001
  Reversibility, per cent                      8.1±8.1      7.7±7.6      17.7±13.0     17.1±12.3     6.8±7.4      9.5±10.6      \<0.001
  Reversibility, mL                            95.2±85.8    108.4±96.5   194.4±139.4   218.0±158.8   96.2±92.9    117.4±120.8   \<0.001
  δ FEV1 (mL/year)                             −34.4±69.8   −12.9±69.2   −50.2±59.0    −12.1±114.5   −42.8±73.3   −31.1±93.4    0.002
  Medication (n, %)                                                                                                             
  Long-acting β 2-receptor agonist             164, 31.7%   31, 29.8%    93, 52.2%     122, 72%      7, 5.5%      12, 6.8%      \<0.001
  Long-acting muscarinic receptor antagonist   181, 35.0%   29, 27.9%    48, 27.0%     4, 2.4%       17, 13.3%    4, 2.3%       \<0.001
  Inhaled corticosteroids                      142, 27.5%   42, 40.4%    129, 72.5%    152, 89.9%    16, 12.5%    27, 15.3%     \<0.001
  Methylxanthine                               60, 11.6%    13, 12.5%    37, 20.8%     22, 13.1%     22, 17.2%    12, 6.8%      \<0.001
  Observation period (year)                    4.3±2.9      4.6±3.2      5.8±3.2       5.9±3.0       4.1±2.8      4.2±2.8       \<0.001

COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; RD, respiratory diseases.

Patient characteristics {#s3b}
-----------------------

The patient characteristics of each group are shown in [table 1](#BMJOPEN2013003541TB1){ref-type="table"}. In total, 176 (13.8%) patients were women, and 1131 (88.9%) patients had a smoking history. All of the patients with COPD and all of the patients with emphysema had smoking histories. Patients with COPD with emphysema had the lowest BMI. The mean %FEV1 was lowest in patients with asthma with emphysema. The annual decline of FEV1 was largest in the patients with asthma with emphysema subgroup and smallest in the patients with COPD without emphysema subgroup.

Mortalities of CAO phenotypes {#s3c}
-----------------------------

The survival curves and rates for the patient subgroups are shown in [figure 2](#BMJOPEN2013003541F2){ref-type="fig"} and online supplementary [table 2](#BMJOPEN2013003541TB2){ref-type="table"}, and the prognostic factors of overall patients are summarised in online supplementary [table S3](#BMJOPEN2013003541TB3){ref-type="table"}. Although other RD with or without emphysema are a mixture of miscellaneous diseases, their survival curves were also presented in [figure 2](#BMJOPEN2013003541F2){ref-type="fig"} for reference. Patients with asthma had better overall survival than patients with COPD when adjusted for other potential variables (see online supplementary [table S3](#BMJOPEN2013003541TB3){ref-type="table"}).

###### 

Univariate and multivariate analysis of the risk of mortality in subgroups

  Subgroup                                 Univariate Cox regression   Multivariate Cox regression final model                                          
  ---------------------------------------- --------------------------- ----------------------------------------- --------- ----------- ---------------- ---------
  COPD with emphysema                                                                                                                                   
   Age, per 1 year increase                1.056                       1.024 to 1.089                            \<0.001   1.038       1.003 to 1.074   0.033
   BMI, per 1 unit increase                0.853                       0.792 to 0.917                            \<0.001   0.904       0.835 to 0.978   0.012
   %FVC, per 1% increase                   0.967                       0.956 to 0.978                            \<0.001   0.965       0.947 to 0.983   \<0.001
   %FEV1, per 1% increase                  0.978                       0.968 to 0.988                            \<0.001                                
   FEV1 reversibility, per 1 mL increase   0.995                       0.992 to 0.998                            0.002                                  
   Use of LABA                                                                                                                                          
    None                                   Reference                   --                                        --                                     
    Positive                               0.628                       0.398 to 0.992                            0.046                                  
   Use of LAMA                                                                                                                                          
   None                                    Reference                   --                                        --                                     
   Positive                                0.547                       0.353 to 0.849                            0.007                                  
  COPD w/o emphysema                                                                                                                                    
   Age, per 1 year increase                1.152                       1.003 to 1.323                            0.045     1.236       1.031 to 1.482   0.022
   %FVC, per 1% increase                   0.952                       0.920 to 0.985                            0.004     0.918       0.854 to 0.985   0.018
   %FEV1, per 1% increase                  0.964                       0.854 to 0.997                            0.030                                  
  Asthma with emphysema                                                                                                                                 
   %FEV1, per 1% increase                  0.952                       0.923 to 0.983                            0.002     0.941       0.905 to 0.979   0.002
   Wheezing                                                                                                                                             
    None                                   Reference                   --                                        --        Reference   --               --
    Positive                               1.431                       1.129 to 1.812                            0.003     1.654       1.236 to 2.213   0.001
   Age, per 1 year increase                1.079                       1.003 to 1.161                            0.041                                  
   FEV1 reversibility, per 1 mL increase   0.994                       0.990 to 0.999                            0.015                                  
  Asthma w/o emphysema                                                                                                                                  
   Age, per 1 year increase                1.174                       1.047 to 1.316                            0.006     1.186       1.008 to 1.394   0.039
   Use of ICSs                                                                                                                                          
    None                                   Reference                   --                                        --        Reference   --               --
    Positive                               0.091                       0.015 to 0.540                            0.008     0.091       0.014 to 0.594   0.012
   %FVC, per 1% increase                   0.938                       0.883 to 0.997                            0.038                                  

BMI, body mass index; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; ICSs, inhaled corticosteroids; LABA, long-acting β 2-adrenergic receptor agonist; LAMA, long-acting muscarinic receptor antagonist; w/o, without.

###### 

Mortality causes in the study groups

                                    COPD with emphysema   COPD without emphysema   Asthma with emphysema   Asthma without emphysema   Other RD with emphysema   Other RD without emphysema   p Value
  --------------------------------- --------------------- ------------------------ ----------------------- -------------------------- ------------------------- ---------------------------- ---------
  Primary respiratory causes        34 (35.7%)            5 (62.5%)                6 (37.5%)               2 (40%)                    15 (51.7%)                7 (33.3%)                    0.020
  Lung cancer                       22 (23.1%)            0                        1 (6.3%)                0                          3 (10.3%)                 2 (9.5%)                     
  Other malignant diseases          10 (10.5%)            0                        1 (6.3%)                0                          1 (3.4%)                  0                            
  Respiratory infectious diseases   6 (6.3%)              1 (12.5%)                3 (18.7%)               0                          2 (6.9%)                  7 (33.3%)                    
  Other causes/unknown              23 (24.2%)            2 (25.0%)                5 (31.2%)               3 (60%)                    8 (27.6%)                 5 (23.8%)                    
  Total number                      95                    8                        16                      5                          29                        21                           

COPD, chronic obstructive pulmonary disease; RD, respiratory diseases.

![Kaplan-Meier survival curves for phenotypes of chronic airflow obstruction. Prognoses between patients with COPD with or without emphysema, and prognoses between patients with asthma with or without emphysema were significantly different by log-rank test (p=0.004 and p=0.016, respectively). COPD, chronic obstructive pulmonary disease; RD, respiratory diseases.](bmjopen2013003541f02){#BMJOPEN2013003541F2}

Patients with asthma and no emphysema had the best prognosis followed by those with asthma with emphysema, COPD without emphysema and COPD with emphysema. Overall survivals between patients with COPD with or without emphysema, and overall survivals between patients with asthma or without emphysema were significantly different by log-rank test (p=0.004 and p=0.016, respectively). Even when adjusted for potential variables, the presence of emphysema was a significant predictor of death in COPD but not in asthma (see online supplementary [table S4](#BMJOPEN2013003541TB4){ref-type="table"}).

###### 

Univariate and multivariate analysis of the risk of de novo lung cancer

  Variables                               Crude OR    95% CI           p Value   Adjusted OR (all variables)   95% CI           p Value   Adjusted OR (selected variables)   95% CI           p Value
  --------------------------------------- ----------- ---------------- --------- ----------------------------- ---------------- --------- ---------------------------------- ---------------- ---------
  Sex                                                                                                                                                                                         
   Female                                 Reference                                                                                                                                           
   Male                                   2.088       0.787 to 5.540   0.139     0.946                         0.343 to 2.608   0.914                                                         
  Age, per 1 year increase                1.037       1.004 to 1.071   0.027     1.028                         0.994 to 1.064   0.108     1.026                              0.993 to 1.060   0.1196
  Smoking history, per 1 cigarette×year   1.000       1.000 to 1.000   0.003     1.000                         0.999 to 1.001   0.171                                                         
  BMI, per 1 unit increase                1.007       0.996 to 1.018   0.231     1.008                         0.993 to 1.024   0.288                                                         
  %FVC, per 1% increase                   1.001       0.989 to 1.013   0.845     1.007                         0.989 to 1.024   0.462                                                         
  %FEV1, per 1% increase                  0.998       0.989 to 1.007   0.641     0.999                         0.985 to 1.014   0.9153                                                        
  Emphysema                               2.602       1.324 to 5.116   0.006     1.513                         0.681 to 3.363   0.309     2.055                              1.042 to 4.053   0.038
  COPD                                    2.367       1.171 to 4.785   0.016     1.125                         0.439 to 2.887   0.806                                                         
  Asthma                                  0.277       0.114 to 0.672   0.046     0.356                         0.144 to 0.885   0.262     0.349                              0.143 to 0.849   0.020
  Other RD                                0.731       0.379 to 1.409   0.350     0.835                         0.408 to 1.710   0.622                                                         

BMI, body mass index; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; RD, respiratory diseases.

Mortality risks from any cause for each clinical subtype except for other RD are shown in [table 2](#BMJOPEN2013003541TB2){ref-type="table"}. Age, BMI and %FVC were independent prognostic factors in COPD with emphysema, whereas age and %FVC were the independent prognostic factors for COPD without emphysema. In the asthma with emphysema subgroup, low %FEV1 and presence of wheezing were negative prognostic factors. In the asthma without emphysema subgroup, age and use of inhaled corticosteroids (ICSs) were significant prognostic factors.

Causes of mortality and de novo lung cancer {#s3d}
-------------------------------------------

There were significant differences in the causes of mortality among the subgroups (Fisher's statistic was 23.59, and the double-sided p value was 0.020, [table 3](#BMJOPEN2013003541TB3){ref-type="table"}). In the COPD with emphysema subgroup, about one-third of the causes of death were de novo malignant diseases and about one-fourth of the cause of death was lung cancer. During the observation period, de novo lung cancers were observed in 38/517 (7.7%) in COPD with emphysema, 5/104 (4.8%) in COPD without emphysema, 4/178 (2.2%) in asthma with emphysema, 2/168 (1.1%) in asthma without emphysema, 8/128 (6.25%) in other RD with emphysema and 3/176 (1.7%) in other RD without emphysema. Therefore, we analysed the risk of de novo lung cancer for the 1272 patients with CAO ([table 4](#BMJOPEN2013003541TB4){ref-type="table"}). The presence of emphysema was a significant predictor for de novo lung cancer (HR 2.055, 95% CI 1.042 to 4.053; p=0.038), and asthma was a negative predictor for de novo lung cancer (HR 0.349, 95% CI 0.143 to 0.849; p=0.020).

Discussion {#s4}
==========

Patients with CAO, postbronchodilator FEV1/FVC always below 0.7, are often diagnosed just as COPD and treated similarly. In this study, we classified the patients with CAO into COPD/asthma/other RD, and then subdivided them by the CT scan findings of emphysema. We showed that COPD comprised only about half of the patients with CAO, and each subgroup had distinct prognosis and prognostic factors. Prognosis of the patients with asthma was better than that of COPD in patients with CAO, and the presence of emphysema was associated with poor prognosis in COPD and asthma. In addition, the presence of emphysema and the presence of asthma were positive and negative risk factors for de novo lung cancer, respectively, in patients with CAO. These data clearly show the impact of differential diagnosis of COPD and usefulness of CT-diagnosed emphysema for the management of patients with CAO.

This study was a retrospective but large-scale single-centre study. In 2000, we introduced a diagnostic algorithm for the patients who showed postbronchodilator FEV1\<0.7.[@R17] HRCT was used to diagnose the presence of emphysema, possible lung cancer, interstitial changes in any lung field, bronchiectasis and miscellaneous diseases of specific clinical entities. Although the present study is retrospective, there is an advantage for diagnosis by having long-term clinical records including responses to ICS treatments. This would be important for diagnosing asthma with similar lung functions to COPD because the presence of intermittent wheezing, variability in the peak flow rate or responses to ICSs might be identified in a follow-up period after initial diagnosis. Sputum eosinophilia and an elevated level of exhaled nitric oxide are well-established markers to distinguish asthma from COPD once fixed airflow obstruction has developed.[@R18] [@R19] We examined these markers to diagnose allergic asthma.

COPD has been thought to be an overlap between chronic bronchitis, emphysema and asthma, and this concept was represented in a Venn diagram and recognised by the ATS.[@R20] [@R21]

We observed that a part of the patients with COPD had no emphysema as best diagnosed by HRCT and careful differential diagnoses. It is not clear whether they have microscopic emphysema, but they had distinct prognosis and prognostic factors from that of COPD with emphysema. The coexistence of asthma and COPD is known as the overlap syndrome.[@R22] [@R23] The overlap syndrome of asthma and COPD has been defined by the coexistence of increased variability of airflow in a patient with incompletely reversible airway obstruction.[@R23] By this definition, all patients with asthma recruited in this study are considered to be a part of the overlap syndrome. In this study, we further classified asthma with CAO by the presence of emphysema. We found that the presence of emphysema predicted poor overall survival in patients with asthma with CAO. Although HR was not significant when adjusted by other potential variables, these subgroups had distinct prognostic factors. In patients with asthma and emphysema, their survival was predicted by the severity of airflow obstruction at a stable period, whereas in patients with asthma without emphysema, the use of ICSs was a critical factor for prognosis regardless of airflow obstruction in a stable state.

Recently, emphysema with the usual interstitial pneumonia or other interstitial pneumonia has attracted as much attention as combined pulmonary fibrosis with emphysema.[@R24] Other RD with or without emphysema comprised 23% of the patients with CAO. HRCT is also useful to detect respiratory comorbidities and other RD. For example, HRCT is sensitive to diagnose interstitial shadows or small airway disease in patients with rheumatoid arthritis.[@R25] However, because these groups are a mixture of miscellaneous diseases, they are not considered as one group. Therefore, we only showed their survival curves just for reference purposes.

One of the main findings of this study is that patients with asthma with CAO had a significantly better prognosis than those with COPD. It is well accepted that disease in patients with asthma who develop incompletely reversible airflow obstruction resembles COPD in terms of age, airway complications and the pattern of airway inflammation with increased presence of airway neutrophils.[@R26; @R27; @R28; @R29] The data of this study seem rather surprising because asthma patients with emphysema had the lowest baseline FEV1 and largest annual decline of FEV1 among patients with CAO. A previous report showed that the prognosis of patients with COPD with airway hyper-responsiveness was worse than that of patients with COPD without airway hyper-responsiveness.[@R30] In that study, which was published in 2000, the patients were recruited from the 1960s to the 1970s, a period before ICSs had become first-line therapy for asthma. In addition, death by lung cancer was accumulated in COPD. It could partially explain the poorer prognosis of COPD compared to asthma with CAO.

In a previous prospective study, published in 2010, the extent of emphysema was associated with COPD prognosis.[@R5] Another study showed that emphysema severity is independently associated with a rapid annual decline in FEV1 in patients with COPD.[@R31] Although the definition of emphysema subgroups is different from that of previous studies,[@R5] [@R31] the results of this study are in accordance with these reports in that the survival rate and annual decline in COPD without emphysema were better than those in COPD with emphysema (p=0.004 by log-rank test, and p=0.008 by Mann-Whitney test, respectively). Low body weight was a poor prognostic factor in patients with COPD with emphysema, but not in patients with COPD without emphysema.

Lung cancer is an important cause of mortality in COPD, and in a recent large cohort study, older age, low BMI, early global initiative for chronic obstructive lung disease stage and low diffusion capacity for carbon monoxide (DLco) were independent risk factors for de novo lung cancer in COPD.[@R32] Among the patients with CAO, we showed that emphysema was a positive risk factor for lung cancer (HR=2.06) and asthma was a negative risk factor (HR=0.35). The result of asthma should be inter-related with caution because it might reflect increased risk for lung cancer in patients without asthma (COPD plus other RD). In fact, recent meta-analysis showed that the relative risk for lung cancer associated with asthma was 1.28.[@R33] However, knowledge of the relative risks for lung cancer may be helpful for the follow-up of patients with CAO.

There are several limitations that should be noted. This study was retrospective, and therefore some clinical and laboratory findings were not available. We could measure residual volume (RV), total lung capacity (TLC) and low DLco in only a portion of the patients at the start of observation; therefore, we excluded these parameters from the analysis of prognosis. In this study, %FVC was a stronger prognostic factor than %FEV1 in patients with COPD, although they were very similar in univariate analysis. %FVC was most closely correlated with RV/TLC (r=−0.730, p\<0.001) among pulmonary function parameters, so reduced %FVC might reflect increased RV/TLC in COPD. In this study, bronchiectasis was diagnosed in a very strict sense.[@R15] Mild dilation of the bronchi in COPD was not considered. Our data are in discordance with a previous report demonstrating the high prevalence of bronchiectasis in COPD.[@R34] If we found real bronchiectasis, we made strong efforts to find a more specific diagnosis such as old tuberculosis, non-tuberculous mycobacterial lung diseases, diffuse panbronchiolitis, bronchial diseases due to rheumatoid arthritis, bronchiolitis obliterans and so on.

In conclusion, patients with not fully reversible airflow obstruction are heterogeneous. Prognosis of the patients with asthma with CAO was better than that of those with COPD in spite of the similar age and lung functions. The presence of emphysema is associated with poor prognosis in COPD and in asthma with CAO. Recognition of HRCT findings of emphysema and allergic asthma in patients with CAO would be important because clinicians could have different strategies for these conditions. The data of this study suggest that the use of ICSs and control of airway obstruction are critically important for the prognosis of asthma with CAO. In patients with COPD with emphysema, preserved body weight and lung functions were important for prognosis, but de novo lung cancer should be considered regardless of age and degree of airflow obstruction.
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